Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 1.00 |
| ▸ | PPARG | P37231 | 18/20 | 1.00 |
| ▸ | RARG | P13631 | 12/20 | 0.90 |
| ▸ | RXRB | P28702 | 5/20 | 0.74 |
| ▸ | RXRG | P48443 | 5/20 | 0.74 |
| ▸ | RARA | P10276 | 4/20 | 0.74 |
| ▸ | RARB | P10826 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29568747 | 1.00 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL4138521 | 1.00 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL726354 | 1.00 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL5960024 | 0.96 | RXRA (0.92) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL726751 | 0.96 | RXRA (0.92) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL726373 | 0.96 | RXRA (0.92) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL6618986 | 0.96 | RXRA (0.92) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL4151576 | 0.91 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL726448 | 0.91 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG | |
| SCHEMBL4151577 | 0.91 | RXRA (1.00) | RXRAPPARGRARGRXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090016991-A1 | Rxr Antagonist Treatment Against Multiple Sclerosis | BOLLAG WERNER | 2009-01-15 | — | — | US | claimed |
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | BOLLAG WERNER | 2008-10-16 | — | — | US | claimed |
| US-20080242729-A1 | Rxr Antagonists in the Treatment of Inflammatory Diseases | BOLLAG WERNER | 2008-10-02 | — | — | US | claimed |
| EP-1771166-A2 | RXR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY DISEASES | Bollag, Werner (CH) | 2007-04-11 | — | — | EP | claimed |
| WO-2006010503-A2 | RXR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY DISEASES | BOLLAG WERNER (CH) | 2006-02-02 | — | — | WO | claimed |
| EP-1621191-A1 | Treatment of inflammatory diseases by RXR Antagonists | Bollag, Werner (CH) | 2006-02-01 | — | — | EP | claimed |
| US-6326397-B1 | OSTEOPOROSIS | HOFFMAN-LA ROCHE INC. | 2001-12-04 | — | — | US | claimed |
| EP-3956026-B9 | P16INK4A INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | UNIV SORBONNE (FR) | 2023-10-04 | — | — | EP | disclosed |
| EP-3956026-B1 | P16INK4A INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | UNIV SORBONNE (FR) | 2023-06-07 | — | — | EP | disclosed |
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | BOLLAG WERNER | 2008-10-16 | — | — | US | disclosed |
| US-20080242729-A1 | Rxr Antagonists in the Treatment of Inflammatory Diseases | BOLLAG WERNER | 2008-10-02 | — | — | US | disclosed |
| US-20060183737-A1 | Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists | BOLLAG WERNER | 2006-08-17 | — | — | US | disclosed |
| EP-1030662-B1 | TREATMENT OF T-HELPER CELL TYPE 2 MEDIATED IMMUNE DISEASES WITH RETINOID ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-08-02 | — | — | EP | disclosed |
| EP-1621191-A1 | Treatment of inflammatory diseases by RXR Antagonists | Bollag, Werner (CH) | 2006-02-01 | — | — | EP | disclosed |
| US-20050227967-A1 | Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists | BOLLAG WERNER | 2005-10-13 | — | — | US | disclosed |
| EP-1161410-B1 | RETINOID ANTAGONISTS AND USE THEREOF | BASILEA PHARMACEUTICA AG (CH) | 2004-05-12 | — | — | EP | disclosed |
| US-20030176420-A1 | Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists | BOLLAG WERNER (CH) | 2003-09-18 | — | — | US | disclosed |
| US-6610742-B1 | Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-6133309-A | TREATING ALLERGIC RHINITIS OR BRONCHIAL ASTHMA, BY ADMINISTERING A RETINOID ANTAGONIST COMPRISING P-(2-(3,4-DIHYDRO-4,4-DIMETHYL-7-(ALKYOXY)-1,1-DIOXIDE-2H-BENZOTHIOPYRAN-6 -YL)PROPENYL)BENZOIC ACID | HOFFMANN-LA ROCHE INC. (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176420-A1 | Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists | RARG, RARA, RXRA | RXRA 3/4885PPARG 117/4885RARG 1/4885 |
| US-20090016991-A1 | Rxr Antagonist Treatment Against Multiple Sclerosis | RXRA, RXRB, RXRG | RXRA 1/4885PPARG 13/4885RARG 8/4885 |
| US-20080242729-A1 | Rxr Antagonists in the Treatment of Inflammatory Diseases | RXRA, RXRB, RXRG | RXRA 1/4885PPARG 11/4885RARG 6/4885 |
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | RXRA, RXRG, RXRB | RXRA 1/4885PPARG 4/4885RARG 8/4885 |
| US-20050227967-A1 | Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists | RARG, RARA, RXRA | RXRA 3/4885PPARG 117/4885RARG 1/4885 |
| US-20060183737-A1 | Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists | RARG, RARA, RXRA | RXRA 3/4885PPARG 117/4885RARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.